Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Amicus Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from ten analysts, with price targets averaging $15.88.
• Recent upgrades from various research firms include ratings from Wall Street Zen and Zacks Research, enhancing investor optimism about the stock's future performance.
• The company's stock currently trades at $8.11 per share, with a market cap of $2.50 billion and significant recent activity from institutional investors increasing their stakes.

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $15.8750.

FOLD has been the topic of several research reports. Wall Street Zen upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, September 20th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Amicus Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Amicus Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 6th. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Finally, Needham & Company LLC upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 price objective on the stock in a research note on Thursday, September 18th.

Institutional Investors Weigh In On Amicus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Diversified Trust Co boosted its stake in Amicus Therapeutics by 2.2% in the 1st quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock worth $682,000 after purchasing an additional 1,784 shares during the period. Tempus Wealth Planning LLC boosted its stake in Amicus Therapeutics by 7.2% in the 1st quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company's stock worth $241,000 after purchasing an additional 1,990 shares during the period. CANADA LIFE ASSURANCE Co lifted its position in Amicus Therapeutics by 2.8% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company's stock worth $480,000 after buying an additional 2,263 shares in the last quarter. Stephens Inc. AR lifted its position in Amicus Therapeutics by 27.4% in the 1st quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company's stock worth $111,000 after buying an additional 2,938 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its position in Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 3,358 shares in the last quarter.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $8.11 on Friday. The firm has a market cap of $2.50 billion, a PE ratio of -67.58 and a beta of 0.56. The firm's 50-day simple moving average is $7.85 and its 200-day simple moving average is $6.90. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics has a 1 year low of $5.51 and a 1 year high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.